Logo

GSK and Hitachi Chemical Signs a Three-year Agreement for T-cell Therapy

Share this

GSK and Hitachi Chemical Signs a Three-year Agreement for T-cell Therapy

Shots:

  • Hitachi Chemical’s subsidiary HCATS (Hitachi Chemical Advanced Therapeutics Solutions)- will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US- Canadian and European trials
  • The agreement focuses on providing- compliant- flexible- scalable- and cost-effective therapies accessible to cancer patients
  • NY-ESO-1 is a human tumor antigen expressed in sarcomas- melanoma- multiple myeloma- bladder cancer- NSCLC- ovarian cancer and gastro-intestinal cancers

 Ref: Businesswire | Image: GSK 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions